ANIMAL CELL;
ARTICLE;
CANCER CELL CULTURE;
CELL CYCLE G2 PHASE;
COLON CARCINOMA;
CONFORMATIONAL TRANSITION;
CONTROLLED STUDY;
CYTOPATHOGENIC EFFECT;
DRUG CONFORMATION;
DRUG DNA BINDING;
DRUG EFFECT;
DRUG MECHANISM;
DRUG SELECTIVITY;
DRUG SOLUBILITY;
DRUG SYNTHESIS;
ENZYME INHIBITION;
HUMAN;
HUMAN CELL;
LEUKEMIA CELL;
LUNG NON SMALL CELL CANCER;
LUNG SMALL CELL CANCER;
MACROMOLECULE;
MITOSIS INHIBITION;
NEUROBLASTOMA CELL;
NONHUMAN;
OVARY CARCINOMA;
SQUAMOUS CELL CARCINOMA;
AMINOGLYCOSIDES;
ANIMALS;
ANTI-BACTERIAL AGENTS;
ANTINEOPLASTIC AGENTS;
AZA COMPOUNDS;
CARBAZOLES;
CELL CYCLE;
DNA;
DNA TOPOISOMERASES, TYPE I;
DRUG SCREENING ASSAYS, ANTITUMOR;
HUMANS;
INDOLES;
MICE;
STRUCTURE-ACTIVITY RELATIONSHIP;
TUMOR CELLS, CULTURED;
Discovery of antitumor indolocarbazoles: Rebeecamycin, NCS 655649, and fluoroindolocarbazoles
Long, B. H.; Rose, W. C.; Vyas, D. M.; Matson, J. A.; Forenza, S. Discovery of antitumor indolocarbazoles: rebeecamycin, NCS 655649, and fluoroindolocarbazoles. Curr. Med. Chem. Anti-Cancer Agents 2002, 2, 255-266.
A phase I clinical and pharmacokinetic study of rebeccamycin analogue (NCS655649) given daily for 5 consecutive days
Dowlati, A.; Remick, S. C.; Majka, S.; Ingalls, S.; Hoppel, C.; Spiro, T.; Gerson, S.; Willson, J. K. V. A phase I clinical and pharmacokinetic study of rebeccamycin analogue (NCS655649) given daily for 5 consecutive days. Proc. Am. Soc. Clin. Oncol. 1999, 18, 181a.
Non camptothecin topoisomerase I active compounds as potential anticancer agents
Long, B. H.; Balasubramanian, B. N. Non camptothecin topoisomerase I active compounds as potential anticancer agents. Expert Opin. Ther. Pat. 2000, 10, 635-666.
Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group
Anizon, F.; Belin, L.; Moreau, P.; Sancelme, M.; Voldoire, A.; Prudhomme, M.; Ollier, M.; Sevère, D.; Riou, J.-F.; Bailly, C.; Fabbro, D.; Meyer, T. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem. 1997, 40, 3456-3465.
Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide nitrogen
Moreau, P.; Anizon, F.; Sancelme, M.; Prudhomme, M.; Bailly, C.; Carrasco, C.; Ollier, M.; Sevère, D.; Riou, J.-F.; Fabbro, D.; Meyer, T.; Aubertin, A.-M. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide nitrogen. J. Med. Chem. 1998, 41, 1631-1640.
Enhanced binding to DNA and topoisomerase I inhibition by an analogue of the antitumor antibiotic rebeccamycin containing an amino sugar residue
Bailly, C.; Qu, X.; Anizon, F.; Prudhomme, M.; Riou, J.-F.; Chaires, J. Enhanced binding to DNA and topoisomerase I inhibition by an analogue of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Mol. Pharmacol. 1999, 55, 377-385.
Syntheses and antiproliferative activities of new rebeccamycin derivatives with the sugar unit linked to both indole nitrogens
Marminon, C.; Anizon, F.; Moreau, P.; Léonce, S.; Pierré, A.; Pfeiffer, B.; Renard, P.; Prudhomme, M. Syntheses and antiproliferative activities of new rebeccamycin derivatives with the sugar unit linked to both indole nitrogens. J. Med. Chem. 2002, 45, 1330-1339.
First synthesis of symmetrical and nonsymmetrical aza indolocarbazoles derivatives
Routier, S.; Coudert, G.; Merour, J. Y.; Caignard, D. H.; First synthesis of symmetrical and nonsymmetrical aza indolocarbazoles derivatives. Tetrahedron Lett. 2002, 43, 2561-2564.
Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group
Anizon, F.; Belin, L.; Moreau, P.; Sancelme, M.; Voldoire, A.; Prudhomme, M.; Ollier, M.; Sevère, D.; Riou, J.-F.; Bailly, C.; Fabbro, D.; Meyer, T. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem. 1997, 40, 3456-3465.
A stereoselective synthesis of indole-β-N-glycosides. An application to the synthesis of rebeccamycin
Gallant, M.; Link, J. T.; Danishefsky, S. J. A stereoselective synthesis of indole-β-N-glycosides. An application to the synthesis of rebeccamycin. J. Org. Chem. 1993, 58, 343-349.
Synthesis and biological activities of NB-506 analogues modified at the glucose group
Ohkubo, M.; Nishimura, T.; Kawamoto, H.; Nakano, M.; Honma, T.; Yoshinari, T.; Arakawa, H.; Suda, H.; Morishima, H.; Nishimura, S. Synthesis and biological activities of NB-506 analogues modified at the glucose group. Bioorg. Med Chem. Lett. 2000, 10, 419-422.
Indolocarbazole poisons of human topoisomerase regioisomeric analogues of ED-110
Zembower, D. E.; Zhang, H.; Lineswala, J. P.; Kuffel, M. J.; Ates, S. A.; Ames, M. M. Indolocarbazole poisons of human topoisomerase regioisomeric analogues of ED-110. Bioorg. Med. Chem. Lett. 1999, 9, 145-150.
In vitro cytotoxicity of S16020-2, a new olivacine derivative
Léonce, S., Pérez, V.; Casabianea-Pignède, M. R.; Anstett, M.; Bisagni, E.; Atassi, G. In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest. New Drugs 1996, 14, 169-180.
